XORTX Therapeutics Inc

XRTX

Company Profile

  • Business description

    XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

  • Contact

    3710 - 33rd Street NW
    CalgaryABT2L 2M1
    CAN

    T: +1 403 455-7727

    https://www.xortx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.5011.400.12%
CAC 408,332.1526.61-0.32%
DAX 4025,369.8535.49-0.14%
Dow JONES (US)49,590.2086.130.17%
FTSE 10010,143.262.560.03%
HKSE26,848.47239.990.90%
NASDAQ23,733.9062.560.26%
Nikkei 22553,549.161,609.273.10%
NZX 50 Index13,656.0527.24-0.20%
S&P 5006,977.2710.990.16%
S&P/ASX 2008,808.5017.200.20%
SSE Composite Index4,138.7626.53-0.64%

Market Movers